.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD16_MetforminAndCanagliflozi.MetforminAndCanagliflozi .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD16_MetforminAndCanagliflozi.MetforminAndCanagliflozi| name: | MetforminAndCanagliflozin |
| ATC code: | A10BD16 | route: | oral |
| n-compartments | 1 |
Metformin and canagliflozin is a fixed-dose combination medication used for the treatment of type 2 diabetes mellitus in adults. Metformin is a biguanide antihyperglycemic agent primarily used to improve glycemic control by decreasing hepatic glucose production and increasing insulin sensitivity, while canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces glucose reabsorption in the kidney, resulting in increased urinary glucose excretion. This combination is currently approved and marketed for medical use.
Pharmacokinetic parameters estimated for average healthy adults, as direct pharmacokinetic parameterization of the fixed-dose combination is not available in publication. Parameters for each component are approximated from studies of individual drugs. Estimated for oral administration of metformin (1000 mg) and canagliflozin (300 mg).
Wattamwar, T, et al., & Pandita, N (2020). Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 1154 122281–None. DOI:10.1016/j.jchromb.2020.122281 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32763846
Scheen, AJ (2015). Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75(1) 33–59. DOI:10.1007/s40265-014-0337-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/25488697